RBC Capital Markets has slightly trimmed its price target for ACADIA Pharmaceuticals, citing seasonal biotech headwinds. The firm also cut its price target for Galapagos NV to $28, while maintaining a Sector Perform rating ahead of its Q1 earnings.

RBC Capital has issued a bullish outlook on PPG Industries (PPG), increasing its price target for the company's stock.

RBC Capital has adjusted its investment position on Unilever, moving away from its previous bearish outlook on the consumer goods giant.

RBC Capital Markets has adjusted its outlook for Becton Dickinson (BDX), trimming its estimates despite stable demand in the MedTech sector.

RBC Capital has reiterated its Outperform rating for ServiceNow (NOW), indicating continued confidence in the company's stock performance.

RBC Capital has adjusted its price target for Ford Motor Company shares, lowering it from $12 to $11.

RBC Capital Markets has upgraded its rating for Asana (ASAN) stock, setting a new price target of $7.

JPMorgan, UBS, and RBC Capital have all increased their price targets for Venture Global (VG), signaling positive outlooks for the company.

RBC Capital has reiterated its "Sector Perform" rating for FactSet Research Systems (FDS).

RBC Capital has increased its price target for Kinder Morgan (KMI) by $3, reflecting an updated outlook on the company's stock.

RBC Capital has adjusted its price target for Exelixis (EXEL) stock downwards to $43.

RBC Capital Markets has reiterated its 'Outperform' rating for Merck (MRK), acknowledging investor concerns regarding a 'modest premium' but maintaining a positive outlook for the pharmaceutical company.

RBC Capital has upgraded Kinross Gold (KGC) stock to Outperform from Sector Perform.

RBC Capital Markets has identified Revolution, Xenon, and Arrowhead as leading candidates for potential takeovers, according to a recent report.

RBC Capital Markets has set a price target of $45 for Kinross Gold (KGC), outlining the conditions required for the stock to reach this valuation.

RBC Capital has raised its price target for Canadian Natural Resources (CNQ), citing strong leadership and shareholder alignment as key factors.

RBC Capital Markets has reiterated its Outperform rating for Nike (NKE), indicating a positive outlook and seeing a clear path to growth for the sportswear giant.

RBC Capital Markets has lowered the price target for Sweetgreen, Inc. (SG) due to a same-store sales outlook that is trailing behind consensus estimates.

RBC Capital has raised its price target for Cheniere Energy Partners shares from $58 to $62.

RBC Capital has raised its price target on Primo Brands Corporation (PRMB) to $29 and maintained an Outperform rating.

RBC Capital lifts CubeSmart's target, Morgan Stanley boosts Fifth Third Bancorp's target, and Morgan Stanley also raises Huntington Bancshares' target, citing banking sector tailwinds.

RBC Capital has begun coverage on KKR & Co. Inc. (KKR) with an 'Outperform' rating.

Several financial firms have issued new ratings, price targets, or coverage initiations for biotech and pharmaceutical companies including Beam Therapeutics, Krystal Biotech, 4D Molecular Therapeutics, BioMarin Pharmaceutical, Vertex Pharmaceuticals, CRISPR Therapeutics AG, Regeneron Pharmaceuticals, and UniQure.

Several financial firms, including Morgan Stanley, Truist, RBC Capital, Goldman Sachs, and Scotiabank, have updated their price targets and ratings for companies like Edison International, Vulcan Materials, Global Payments, Insulet, Quanta Services, A. O. Smith, FirstEnergy, and Targa Resources.

RBC Capital initiates coverage on Bristol Myers (BMY) with a $60 target, noting the depth of its late-stage pipeline.

RBC Capital Markets has upgraded its rating for pharmaceutical company AbbVie to 'outperform,' citing expectations for durable growth.

RBC Capital analysts have suggested that Eagle Materials could be worth more if split into two separate entities, according to a new analysis.

RBC Capital suggests that a shift in tariff policy is unlikely to negatively impact U.S. stocks, offering an analysis of the economic outlook.

RBC Capital has increased its price target for Prologis (PLD) due to an improved outlook for industrial real estate.

Several financial institutions, including Stifel, Scotiabank, and Jefferies, have issued updated price targets and ratings for various companies. These reports reflect analysts' current outlooks on stock performance and investment recommendations.

RBC Capital has maintained its Outperform rating on Shopify (SHOP), citing a strong growth outlook for the company.

RBC Capital Markets has increased its price target for Vertex Pharmaceuticals (VRTX) as it updates its outlook for the biotech sector. This reflects a positive analyst sentiment towards the company.

RBC Capital has raised its price target for Dow (DOW) to $47, indicating a more positive outlook on the company's stock.

RBC Capital has reaffirmed its 'Outperform' rating for Adobe (ADBE) stock, indicating continued confidence in the company's performance.

RBC Capital Markets has downgraded the ratings for oilfield services companies NOV and Trican Well Services.

Morgan Stanley and RBC Capital have both increased their price targets for CF Industries, citing robust fertilizer prices as the primary reason.

RBC Capital Markets has reduced its price target for UBS while simultaneously adjusting its assumptions regarding the bank's Assets Under Management (AUM).

RBC Capital Markets has downgraded Ivanhoe Mines' stock rating, citing expectations of materially lower near-term production for the mining company.

RBC Capital has increased its price target for Enterprise Products Partners (EPD) to $42, indicating a positive outlook for the company's stock.

RBC Capital Markets has initiated coverage of Sonida Senior Living with a 'Buy-equivalent' rating.

RBC Capital Markets has maintained its Outperform rating on Union Pacific (UNP), while also flagging higher Q1 EPS and potential approval risks for the railway company.

JPMorgan has increased its price target for Edison International (EIX) from $66 to $74, reflecting a positive adjustment in its valuation of the utility holding company.

Investment firms RBC Capital and Jefferies have reiterated their bullish ratings on Microsoft (MSFT), signaling continued confidence in the technology giant's stock performance.

Lofty investor expectations for growth and a balanced risk-reward ratio make shares of Starbucks less compelling, according to RBC Capital Markets.

RBC Capital has reiterated its 'Outperform' rating on Enbridge Inc. (ENB), signaling continued confidence in the company's stock performance.

RBC Capital has increased its price target for APA, citing strong oil prices and positive earnings momentum as key factors supporting the company's shares.

RBC Capital Markets has raised its price target for Broadcom (AVGO), citing bullish commentary regarding the company's financial outlook for fiscal year 2027.

RBC Capital has lowered its price target on Autodesk, Inc. (ADSK) stock, reflecting a revised outlook on the design software company.

RBC Capital has maintained its bullish outlook on TPG (TPG).

RBC Capital has lowered its price target for Viridian Therapeutics, Inc. (VRDN) to $42, while still maintaining an Outperform rating on the stock.

RBC Capital has downgraded Clearwater Analytics Holdings, Inc. (CWAN) to Sector Perform and lowered its price target to $24.55.

RBC Capital has lowered its target price on Fidelity National Information Services (FIS) to $69, following a slight miss in its fourth-quarter earnings.

RBC Capital has reduced its price target for Clarivate Plc (CLVT) after the company released its Q4 2025 financial results.

Multiple financial institutions have updated their price targets and ratings for various companies, reflecting new outlooks on their performance and market conditions.

RBC Capital Markets has reduced its price target for Leidos Holdings, Inc. (LDOS) from $230 to $215, citing a service-focused valuation.

RBC Capital initiates coverage on Pfizer (PFE) with a $25 target, highlighting structural revenue headwinds.

Ares Management Corporation is scheduled to present at the 2026 RBC Capital Markets Global Financial Institutions Conference, likely to discuss its financial performance and outlook.

RBC Capital has increased its price outlook for Lowe's (LOW) following strong performance trends observed in January.

RBC Capital Markets has downgraded Imperial Oil, citing that the company's valuation has become 'stretched' following several years of strong stock performance.

RBC Capital has lowered its price target for Figma, Inc. (FIG) to $31 while maintaining a Sector Perform rating on the stock.

Analysts are bullish on several biotech companies, including GH Research, Cybin D/B/A Helus Pharma, and COMPASS Pathways, following a psychedelics symposium and positive model updates, with Baird lowering Bright Minds Biosciences' price target but maintaining an Outperform rating.

RBC Capital has lowered its price target for Zeta Global Holdings (ZETA) to $27, indicating a revised outlook for the company's stock.

RBC Capital has increased its price target for Restaurant Brands International (QSR) stock, citing continued positive momentum for the company.

RBC Capital Markets has upgraded its rating for Unilever (UL) stock from its previous position to 'Sector Perform'. This change reflects a revised outlook on the consumer goods giant's market performance.

RBC Capital has shown upward momentum in its price target for LyondellBasell (LYB), indicating a positive outlook for the company.

RBC Capital has raised its price target for Incyte Corporation (INCY) from $92 to $95. This upward adjustment reflects a more positive financial outlook for the biopharmaceutical company.

RBC Capital Markets has adjusted its price targets for several companies, trimming Procter & Gamble's target due to modest growth while lifting Chevron's target as its commodity view improves.

RBC Capital has lowered its price target for Autoliv from $141 to $137 and for Dauch Corporation from $10 to $9. These adjustments reflect updated financial outlooks for both companies.

RBC Capital has reiterated its 'Outperform' rating for Wave Life Sciences (WVE), indicating a continued positive outlook on the biotechnology company's stock.

RBC Capital has increased its price target for Nutrien (NTR) in anticipation of the company's first-quarter earnings report. The adjustment is attributed to strong fertilizer prices, signaling positive expectations for Nutrien's performance.

Baird, a financial services firm, has reduced its price target for Nyxoah SA (NYXH) shares from $5.87 to $4.62. This adjustment reflects a revised outlook on the company's financial performance or market conditions.

RBC Capital attributes FactSet's strong second-quarter performance to competitive wins and increased pricing strategies. This analysis follows FactSet's reported Q2 beat.

BMO Capital has reduced its price target for BioNTech SE (BNTX) from $143 to $128.

RBC Capital has reduced its price target on Graphic Packaging (GPK) from $13 to $10, reflecting a revised outlook for the company's stock.

RBC Capital Markets has increased its stock price target for Canadian National (CN) for the year 2027, indicating a positive outlook for the railway company.

RBC Capital has reduced its price target for FactSet Research Systems (FDS) from $320 to $243.

RBC Capital has reiterated its 'Sector Perform' rating for Advanced Micro Devices (AMD) stock.

RBC Capital Markets has identified weaknesses in the housing market as a significant risk factor for Installed Building Products, Inc. (IBP).

RBC Capital has increased its price target for Nuvation Bio (NUVB) from $12 to $13, citing reasons for the upward adjustment.

RBC Capital and Bernstein have both raised their price targets for Eaton Corporation plc (ETN), reflecting a positive outlook for the company's stock.

RBC Capital suggests that Ollie's Bargain Outlet faces a 'noisy' first quarter, but its 2026 prospects are underestimated by investors.

RBC Capital has reduced its price target for Broadcom Inc. (AVGO) from $370 to $340, citing specific reasons for the adjustment.

Wix.com price target lowered to $112 from $155 at RBC Capital  The Globe and Mail

RBC Capital has raised its price target for HSBC Holdings (HSBC) while maintaining a 'Hold' rating on the stock.

Morgan Stanley and RBC Capital both raise their target forecasts for Kinder Morgan.

RBC Capital Markets has issued a note indicating that CareTrust REIT, Inc. (CTRE) is well-positioned, even amid increased general and administrative expenses and investment timing considerations.

RBC Capital has reiterated its 'Hold' rating on Rio Tinto Group (RIO), indicating a neutral outlook on the mining company's stock.

RBC Capital Markets has increased its price objective for The Bank of Nova Scotia (BNS), citing an improving credit outlook for the bank.

RBC Capital has expressed a favorable view on Voya Financial's (VOYA) fourth-quarter performance, suggesting positive analyst sentiment.

RBC Capital has increased its price target for Home Depot shares from $363 to $377.

RBC Capital projects that Merck (MRK) will return to growth sooner than market expectations.

Ares Management Corporation to Present at the 2026 RBC Capital Markets Global Financial Institutions Conference  The Globe and Mail

RBC Capital has reiterated its rating on Fiserv, Inc. (FISV) after the company exceeded its Q4 earnings expectations.

RBC Capital has reduced its price target on Autodesk, Inc. (ADSK) to $340 while maintaining an Outperform rating.

Several financial institutions have updated their price targets for a range of companies, including CytomX Therapeutics, Upwork, Coursera, Tripadvisor, and The Wendy's Company, while maintaining various ratings.